FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series A / Biotech startups that raised Series A in DACH

Biotech startups that raised Series A in DACH

Updated 16 Nov 2026

Reset
Biotech startups that raised Series A in DACH
One-time CSV
  • 130 funded companies, 71 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-a~dach.csv130 rows × 18 columns
CompanyCityLast roundAmountDate
Cellbox SolutionsCologneSeries A$1.7M2026-10-20
Adaptyv BiosystemsLausanneSeries A$40.0M2026-08-25
mbiomicsMunichSeries A$12.0M2026-04-28
KupandoSchönefeldSeries A$11.5M2026-03-18
Leman BiotechLausanneSeries A$28.8M2026-01-26
FoRx TherapeuticsBaselSeries A$50.0M2025-12-18
ComphyaLausanneSeries A$4.0M2025-07-08
AdipossGenevaSeries A$5.0M2025-06-30

8 rows of the CSV in 5 of its 18 columns.

130
Startups
$1.6B
Total raised
12
Funded in the last 12 months
$214.3M
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 130
30 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
Cellbox Solutions Cellbox Solutions provides logistics solutions for the global biomedical industry. Biotech Cologne, Germany Series A $1.7M 2026-10-20 $15.3M European Innovation Council, Fraunhofer Venture, CK Venture Capital 11 to 50 2017
Adaptyv Biosystems Adaptyv Biosystems develops protein engineering tools using cell-free synthetic biology and nanofluidics technology. Artificial intelligence Lausanne, Switzerland Series A $40.0M 2026-08-25 $50.9M Y Combinator, Venture Kick, Acequia Capital (AceCap) +2 11 to 50 2020
mbiomics mbiomics is a biotechnology company. Biotech Munich, Germany Series A $12.0M 2026-04-28 $26.1M HTGF (High-Tech Gruenderfonds), Bayern Kapital, MIG Capital 11 to 50 2020
Kupando Kupando is a biopharmaceutical company developing agonists that stimulate innate immunity. Biotech Schönefeld, Germany Series A $11.5M 2026-03-18 $24.0M HTGF (High-Tech Gruenderfonds), Brandenburg Kapital, Remiges Ventures +2 1 to 10 2018
Leman Biotech Leman Biotech develops cancer immunotherapies as a biotech company. Biotech Lausanne, Switzerland Series A $28.8M 2026-01-26 $46.8M Tiantu Capital, Fuho Capital 11 to 50 2021
FoRx Therapeutics FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. Biotech Basel, Switzerland Series A $50.0M 2025-12-18 $109.4M EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 11 to 50 2019
Comphya Comphya develops an active implantable medical device to restore erectile function in patients who do not respond to oral drugs. Biotech Lausanne, Switzerland Series A $4.0M 2025-07-08 $14.2M Venture Kick, Verve Ventures, Nest Collective Foundation 1 to 10 2017
Adiposs Adiposs SA is a clinical-stage life science company developing a first-in-class imaging product for cancer patients. Biotech Geneva, Switzerland Series A $5.0M 2025-06-30 $7.4M MassChallenge, Venture Kick, FONGIT Innovation Fund +2 1 to 10 2020
Rhygaze Rhygaze develops a gene therapy that targets cone cells to restore vision in blinding diseases. Biotech Basel, Switzerland Series A $86.0M 2025-01-10 $97.3M Google Ventures, F-Prime, ARCH Venture Partners +2 11 to 50 2024
invIOs invIOs is a private biotech company that discovers and develops cancer therapies. Biotech Vienna, Austria Series A $8.9M 2024-10-15 $12.9M The Austrian Research Promotion Agency (FFG), Ligand Pharmaceuticals 11 to 50 2019
Mindpeak Mindpeak develops AI-based diagnostic software that detects, quantifies, and classifies cancer. Artificial intelligence Hamburg, Germany Series A $15.3M 2024-09-30 European Innovation Council, EIC Accelerator, Nina Capital +2 11 to 50 2018
PL BioScience PL BioScience delivers 2D and 3D cell culture solutions based on human Platelet Lysate. Biotech Aachen, Germany Series A $8.5M 2024-08-08 $13.0M TechVision Fund, better ventures, Brightlands Venture Partners +1 11 to 50 2015
Neurosterix Neurosterix is a biopharmaceutical firm creating allosteric modulators for neurological illnesses. Biotech Geneva, Switzerland Series A $65.0M 2024-04-03 $65.0M Perceptive Advisors, Xontogeny, Acorn Bioventures 11 to 50 2024
G.ST Antivirals G.ST Antivirals is a clinical-stage biotech company developing broad-spectrum antivirals for respiratory tract infections. Biotech Vienna, Austria Series A $6.7M 2024-01-25 Lansdowne Partners, XISTA Science Ventures 11 to 50 2019
Scailyte Scailyte delivers precision medicine through single-cell science. Artificial intelligence Basel, Switzerland Series A $1.8M 2023-12-04 $15.6M Venture Kick, Verve Ventures, Innosuisse +2 11 to 50 2017
traceless materials traceless materials develops circular bioeconomy alternatives to conventional plastics and bioplastics. Biotech Hamburg, Germany Series A $38.8M 2023-09-25 HTGF (High-Tech Gruenderfonds), European Innovation Council, Planet A Ventures +2 51 to 100 2020
TOLREMO therapeutics TOLREMO therapeutics develops small molecules that target drug resistance pathways in cancer therapy. Biotech Zürich, Switzerland Series A $37.9M 2023-09-20 Altos Ventures, redalpine, BioMedPartners +1 11 to 50 2017
NewBiologix NewBiologix is a technology innovation company. Biotech Epalinges, Switzerland Series A $50.3M 2023-05-11 $50.3M Recipharm Venture Fund 11 to 50 2023
anvajo anvajo is a Dresden-based company that develops, manufactures and sells liquid analysis solutions. Biotech Dresden, Germany Series A $17.3M 2022-10-19 Think.Health, Die Brückenköpfe, Johnsonville Ventures 51 to 100 2016
Vector BioPharma Vector BioPharma develops gene precision delivery technology to improve biologics. Biotech Basel, Switzerland Series A $30.0M 2022-08-10 $30.0M Versant Ventures 11 to 50 2021
CDR-Life AG CDR-Life AG develops therapeutic antibody fragments for immuno-oncology. Biotech Schlieren, Switzerland Series A $76.0M 2022-04-13 $76.0M RA Capital Management, Omega Funds, Jeito Capital 51 to 100 2017
Cimeio Therapeutics Cimeio Therapeutics develops curative treatments for genetic diseases, blood cancers, and severe autoimmune disorders. Biotech Basel, Switzerland Series A $50.0M 2022-04-13 $50.0M Versant Ventures 11 to 50 2020
Embion Technologies Embion Technologies offers industrial biomass processing technology for nutrition, pharma, and cosmetics applications. Biotech Lausanne, Switzerland Series A $4.9M 2021-12-08 Venture Kick, Foundation for Innovation and Technology (FIT), Swiss Economic Award 1 to 10 2016
Platomics Platomics is an accelerator program for in vitro diagnostics companies. Biotech Vienna, Austria Series A $16.4M 2021-09-21 $16.4M GreyBird Ventures 101 to 250 2014
Anjarium Biosciences Anjarium Biosciences develops non-viral gene therapies to treat genetic diseases. Biotech Schlieren, Switzerland Series A $60.4M 2021-09-15 Gimv, Omega Funds, Pfizer Venture Investments +2 1 to 10 2017
Cortical.io Cortical.io offers AI solutions for intelligent document processing based on neuroscience-inspired technology. Artificial intelligence Vienna, Austria Series A $6.0M 2021-09-14 $21.3M European Investment Bank, Open Field Capital 11 to 50 2011
GeneQuine Biotherapeutics GeneQuine Biotherapeutics develops gene therapy for treating osteoarthritis. Biotech Hamburg, Germany Series A $6.6M 2021-02-15 HTGF (High-Tech Gruenderfonds), IFB Innovationsstarter, Meusinvest (Noshaq) 1 to 10 2011
Chord Therapeutics Chord Therapeutics is a clinical stage biopharmaceutical company developing drugs for rare diseases. Biotech Geneva, Switzerland Series A $16.0M 2020-10-13 Omega Funds, Eclosion SA 1 to 10 2014
POLYNEURON Polyneuron is a pharmaceutical company developing a new drug class for autoimmune disorders. Biotech Basel, Switzerland Series A $15.4M 2020-09-16 $45.0M New Enterprise Associates, Venture Kick, Sofinnova Partners +1 1 to 10 2014
Arvelle Therapeutics Arvelle Therapeutics is a biopharmaceutical company developing medicines for patients. Biotech Basel, Switzerland Series A $42.7M 2020-05-27 KB Investment, F-Prime, EQT Life Sciences +2 51 to 100 2019

Table 1. Biotech startups that raised Series A in DACH: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 130.

Largest rounds

Last 12 months
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 FoRx Therapeutics FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. Biotech Basel, Switzerland Series A $50.0M 2025-12-18 $109.4M EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 11 to 50 2019
2 Adaptyv Biosystems Adaptyv Biosystems develops protein engineering tools using cell-free synthetic biology and nanofluidics technology. Artificial intelligence Lausanne, Switzerland Series A $40.0M 2026-08-25 $50.9M Y Combinator, Venture Kick, Acequia Capital (AceCap) +2 11 to 50 2020
3 Leman Biotech Leman Biotech develops cancer immunotherapies as a biotech company. Biotech Lausanne, Switzerland Series A $28.8M 2026-01-26 $46.8M Tiantu Capital, Fuho Capital 11 to 50 2021
4 mbiomics mbiomics is a biotechnology company. Biotech Munich, Germany Series A $12.0M 2026-04-28 $26.1M HTGF (High-Tech Gruenderfonds), Bayern Kapital, MIG Capital 11 to 50 2020
5 Kupando Kupando is a biopharmaceutical company developing agonists that stimulate innate immunity. Biotech Schönefeld, Germany Series A $11.5M 2026-03-18 $24.0M HTGF (High-Tech Gruenderfonds), Brandenburg Kapital, Remiges Ventures +2 1 to 10 2018
6 Cellbox Solutions Cellbox Solutions provides logistics solutions for the global biomedical industry. Biotech Cologne, Germany Series A $1.7M 2026-10-20 $15.3M European Innovation Council, Fraunhofer Venture, CK Venture Capital 11 to 50 2017

Table 2. Biotech startups that raised Series A in DACH: the 6 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 HTGF (High-Tech Gruenderfonds) Venture capital firm Bonn, Germany 22 17% 2 mbiomics, Kupando
2 Venture Kick Startup incubator Schlieren, Switzerland 10 8% 1 Adaptyv Biosystems
3 KfW Government investment office Frankfurt, Germany 6 5%
4 Foundation for Innovation and Technology (FIT) Entrepreneurship program Lausanne, Switzerland 5 4% 1 Adaptyv Biosystems
5 Bayern Kapital Venture capital firm Landshut, Germany 5 4% 1 mbiomics
6 EQT Life Sciences Private equity firm Amsterdam, The Netherlands 5 4% 1 FoRx Therapeutics
7 Novartis Venture Fund Corporate venture arm Basel, Switzerland 4 3% 1 FoRx Therapeutics
8 Omega Funds Secondary purchaser Boston, United States 4 3% 1 FoRx Therapeutics
9 BioMedPartners Venture capital firm Basel, Switzerland 4 3%
10 Fraunhofer Venture Venture capital firm Munich, Germany 3 2% 1 Cellbox Solutions
11 European Innovation Council Startup accelerator Brussels, Belgium 3 2% 1 Cellbox Solutions
12 Andera Partners Private equity firm Paris, France 3 2%
13 Versant Ventures Venture capital firm Menlo Park, United States 3 2%
14 Gilde Healthcare Private equity firm Utrecht, The Netherlands 3 2%
15 EMBL Ventures Venture capital firm Heidelberg, Germany 3 2%

Table 3. Biotech startups that raised Series A in DACH: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 102 78% $1.2B
Software 13 10% $123.3M
Artificial intelligence 9 7% $106.9M
Hardware 2 2%
Fintech 1 1% $21.3M
Education 1 1%

Table 4. Biotech startups that raised Series A in DACH by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series A 130 100% $8.9M

Table 5. Biotech startups that raised Series A in DACH by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
Germany 58 45%
Switzerland 56 43%
Austria 15 12%
Liechtenstein 1 1%

Table 6. Biotech startups that raised Series A in DACH by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Basel 13 10%
Lausanne 10 8%
Vienna 10 8%
Schlieren 6 5%
Munich 5 4%
Geneva 5 4%
Hamburg 5 4%
Berlin 5 4%
Martinsried 4 3%
Epalinges 4 3%
Zürich 3 2%
Neuchâtel 3 2%

Table 7. Biotech startups that raised Series A in DACH by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
October 2026 2 17% $6.5M
September 2026 2 17% $13.7M
August 2026 1 8% $40.0M
April 2026 2 17% $32.5M
March 2026 2 17% $22.8M
January 2026 1 8% $28.8M
December 2025 2 17% $70.0M

Table 8. Biotech startups that raised Series A in DACH: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 10 8% $144.3M
2025 8 6% $230.0M
2024 13 10% $258.7M
2023 7 5% $153.7M
2022 6 5% $193.5M
2021 16 12% $298.2M

Table 9. Biotech startups that raised Series A in DACH by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 3 2%
2020 to 2022 17 13%
2015 to 2019 43 33%
2010 to 2014 35 27%
Before 2010 31 24%

Table 10. Biotech startups that raised Series A in DACH by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 47 37%
11 to 50 65 51%
51 to 100 10 8%
101 to 250 3 2%
251 to 500 1 1%
501 to 1,000 2 2%

Table 11. Biotech startups that raised Series A in DACH by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in DACH whose last round is Series A are on the list?
130, in the file dated 16 November 2026. 12 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 130 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series A in DACH: 130 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in DACH

Other sectors that raised Series A in DACH

Cite: FundingWatcher, 130 biotech companies in DACH whose most recent round is Series A, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-a/dach/